ZVRA Q4 2023 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+469.9% YoY

Gross Profit

$10M78.9% margin

Operating Income

-$15M-111.0% margin

Net Income

-$15M-114.6% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+356.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$172M

Total Liabilities

$110M

Stockholders' Equity

$62M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$2M	+469.9%
Gross Profit	$10M	$2M	+379.4%
Operating Income	-$15M	-$9M	-58.6%
Net Income	-$15M	-$9M	-68.0%